Alembic Pharmaceuticals Launches Pivya Antibiotic in US Market

Alembic Pharmaceuticals has launched and commenced sales of Pivya (pivmecillinam) tablets, its first branded pharmaceutical product in the US. Marketed through its wholly owned subsidiary Alembic Therapeutics LLC, Pivya is an oral antibiotic for treating uncomplicated urinary tract infections in women. The company aims to build a focused branded specialty portfolio in the US, leveraging this product to enter a stable therapeutic category with established clinical efficacy and safety.